10-Q: Regenerex Pharma Reports Wider Q2 Loss, Going Concern Doubts Amid Zero Revenue

Regenerex Pharma, Inc. reported a significantly increased net loss of $663,584 for Q2 2025, with zero revenue and substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended June 30, 2025, increased to $663,584, compared to $272,560 for the same period in 2024.
• The company generated no revenue during both the three months ended June 30, 2025, and 2024.
• Cash and equivalents decreased significantly to $172,430 as of June 30, 2025, from $653,025 as of March 31, 2025.
• Accumulated deficit grew to $8,806,475 as of June 30, 2025, with total liabilities exceeding assets by $4,547,656.
• Management expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for significant capital.
• The contingent consideration rate for the November 2021 intellectual property purchase was amended in January 2025 to 25% of all investment money raised, up from 15%.
• A $2,400,000 note payable for technology platforms, originally due August 2024, was extended to August 16, 2025, due to not raising $10,000,000 in sales or investment.
• Subsequent to the quarter, $250,000 in stock was issued at $1.00 per share with warrants, yielding net proceeds of $162,500 after fees and CEO note repayment.
• A binding Letter of Intent was signed with Colltech Limited on July 11, 2025, for an exclusive worldwide partnership for ovine collagen wound care products.

Sentiment

Score: 3

Explanation: The company faces severe financial distress with widening losses, zero revenue, and a going concern warning. While there are positive developments in product efficacy and strategic partnerships, the immediate financial outlook and internal control issues are highly concerning, indicating significant operational and financial risk.

Positives

• Secured a binding Letter of Intent with Colltech Limited for an exclusive worldwide partnership for ovine collagen wound care products, expanding product portfolio and market reach.
• The plant facility has received FDA approval for the production of Xcellderma OTC, indicating progress towards commercialization.
• Management is actively developing managed care agreements with southeastern states for Medicaid wound care patients and discussing federally funded programs in Puerto Rico.
• The company's proprietary active ingredient, QBx, has demonstrated high efficacy in clinical trials, achieving up to 95% closure rates for non-responding chronic wounds.
• The company successfully raised $250,000 in stock and warrants subsequent to the quarter end, providing some capital.

Negatives

• Net loss significantly widened to $663,584 for Q2 2025, compared to $272,560 in Q2 2024.
• The company reported zero revenue for both the current and prior year's second quarter.
• Cash and equivalents decreased by over 73% from $653,025 at March 31, 2025, to $172,430 at June 30, 2025.
• Accumulated deficit increased to $8,806,475, and total liabilities exceed total assets by $4,547,656, raising substantial doubt about the company's ability to continue as a going concern.
• Cash used in operating activities increased dramatically to $477,943 in Q2 2025 from $55,332 in Q2 2024.
• Financing activities shifted from providing $54,960 in cash in Q2 2024 to using $2,652 in Q2 2025.
• The $2,400,000 note payable for technology platforms required an extension due to the company's failure to raise $10,000,000 in sales or investment.
• Management concluded that internal control over financial reporting was not effective as of June 30, 2025, citing material weaknesses due to a lack of in-house technical knowledge for complex transactions.
• The contingent consideration rate for a related party asset purchase was increased to 25% of investment money, potentially increasing future payouts from capital raises.

Risks

• Ability to add new customers.
• Potential benefits of and ability to maintain relationships, establish future collaborations or strategic relationships, or obtain additional funding.
• Marketing capabilities and strategy.
• Ability to maintain a cost-effective program.
• Ability to retain key professionals and to identify, hire, and retain additional qualified professionals.
• Competitive position, and developments and projections relating to competitors and the industry.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.
• Impact of laws and regulations.
• Impacts of future pandemics on business, results of operations, financial position, and cash flows.
• Lack of revenue history and limited history of operations.
• No revenue historically derived from purchased assets.
• No assurance of success or profitability.
• Inability to raise sufficient capital or meet financing requirements, potentially leading to curtailment of operations, seeking capital on less favorable terms, and/or other remedial measures.
• Inherent limitations in internal control systems, including faulty judgments, circumvention by individuals or management override, and controls becoming inadequate due to changing conditions or resource constraints.

Future Outlook

Management plans to actively seek capital to launch its business, add new products/services, and achieve profitability. The company expects to launch its sales initiative during the second quarter of its fiscal year ending March 31, 2026 (July-September 2025). It is also engaged in developing managed care agreements with southeastern states for Medicaid wound care patients and discussing federally funded programs in Puerto Rico. A binding Letter of Intent for an exclusive worldwide partnership for ovine collagen products is expected to be finalized by August 31, 2025, with a detailed long-form contract by March 31, 2026, for scaled commercial operations.

Management Comments

• Our future operating results, however, are impossible to predict and no representation, guaranty, or warranty is to be inferred from those forward-looking statements.
• Currently management is engaged in developing managed care agreements with southeastern states to manage their Medicaid wound care patients.
• Regenerex would provide our wound care products and protocols which would result in a large savings for the state Medicaid population.
• The Company is also in the process of negotiating with several distributors in various Middle Eastern countries to provide the Company's products.
• We expect to launch our sales initiative during the Company's second quarter of our fiscal year ending March 31, 2026.
• Management's plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability.
• Management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital.
• Management concluded that the Company did not maintain effective internal control over financial reporting as of June 30, 2025.
• Management will continue to seek guidance from third-party experts and consultants to gain a thorough understanding of these transactions.

Industry Context

Regenerex Pharma operates in the advanced wound care healing products market, a sector facing significant challenges due to the growing prevalence of chronic wounds, particularly among an aging population and those with diabetes and obesity. The company's focus on proprietary technologies like QBx, which addresses elevated protease levels in chronic wounds, positions it within a niche aiming for high efficacy where conventional treatments often fail. The reported 95% closure rates in clinical trials for non-responding chronic wounds suggest a potentially disruptive technology. The recent binding Letter of Intent with Colltech Limited for ovine collagen products indicates a strategic move to diversify its product offerings and expand into the global market, leveraging established collagen-based wound care solutions. However, the company's lack of revenue and significant losses highlight the substantial capital requirements and market penetration challenges typical for early-stage biotech and medical device companies in this competitive industry.

Comparison to Industry Standards

• The company's reported 95% closure rate for non-responding chronic wounds within 90 days, achieved with its Wound Closure System and QBx technology, significantly outperforms many conventional treatments which often struggle with chronic wound healing. For example, standard care for diabetic foot ulcers typically shows closure rates ranging from 24% to 31% at 12 weeks, and even advanced therapies like bioengineered skin substitutes or negative pressure wound therapy often report closure rates in the 50-70% range over similar periods.
• The FDA approval for the Xcellderma OTC plant is a critical milestone, aligning with regulatory standards required for commercialization in the U.S. market, similar to other over-the-counter medical products.
• The company's current financial state, characterized by zero revenue, substantial net losses, and a going concern warning, is not uncommon for early-stage pharmaceutical or medical device companies focused on R&D and market entry. However, the magnitude of the cash burn ($477,943 in Q2 2025 operating activities) relative to its cash reserves ($172,430) indicates a more precarious liquidity position compared to well-capitalized industry peers or those with established revenue streams.
• The reliance on related party financing and the increase in contingent consideration for intellectual property to 25% of investment money could be seen as less favorable compared to financing structures of more mature companies, potentially diluting future equity raises or increasing cost of capital.

Corporate Governance

Legal Proceedings

• As of June 30, 2025, the Company is not involved in any material litigation.

Related Party Transactions

• Assets were purchased from the company's current Chief Executive Officer (CEO) and Secretary/Treasurer.
• The company has a plant facility lease agreement with Woundcare Labs, LLC, a party related to the CEO, commencing June 9, 2023, with monthly rental payments of $18,000 (except June 2023) and annual equipment rent of $10,000.
• An agreement was entered into on May 23, 2025, with Optimize Health Partners, LLC, a party related to the CFO, to develop and provide information technology systems.
• The CEO advanced $0 to the company during the three months ended June 30, 2025, and $1,600 during the same period in 2024, for operating expenses. Total related party advances were $0 as of June 30, 2025.
• The CEO advanced $0 to the company during the three months ended June 30, 2025, and $53,360 during the same period in 2024, for operating expenses. Repayments totaled $17,652 in Q2 2025. These notes bear 10% interest and are due September 30, 2025, with a total outstanding of $295,664 as of June 30, 2025.
• Various promissory notes with a total outstanding principal and accrued interest of $486,112 as of June 30, 2025, are due to a shareholder of the company, bearing 10% interest and due September 30, 2025.
• A note agreement for $184,232 plus interest with a relative of a former Company Officer was renewed until June 30, 2026.
• The contingent consideration for the November 15, 2021, Asset Purchase Agreement (related to CEO/Secretary/Treasurer) was amended in January 2025 to 25% of all gross investment money raised, up from 15%. Total $651,500 has been paid under this agreement through June 30, 2025.
• The $2,400,000 note payable for technology platforms (related to CEO/Secretary/Treasurer) was extended due to the company not meeting a $10,000,000 sales or investment threshold.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing capital raises and equity plans, increased accumulated deficit, and substantial doubt about the company's going concern status. The increase in contingent consideration to 25% of investment money could reduce net proceeds from future capital raises.
• Creditors: Notes payable to related parties, shareholders, and a relative of a former officer are significant, with several maturities approaching (September 30, 2025, August 16, 2025, June 30, 2026), posing repayment risk given the company's liquidity issues.
• Employees/Management: The 2025 Equity Plan provides significant stock options (e.g., 4,000,000 options for the CFO), potentially incentivizing key personnel despite the company's financial challenges.
• Customers/Patients: Potential future beneficiaries of advanced wound care products (Xcellderma, Accelerex, QBx) if the company successfully commercializes and distributes them, particularly for chronic wounds.
• Suppliers: The company's significant accounts payable and liquidity issues could pose risks for timely payments to suppliers.

Next Steps

• Actively seek capital to launch business, add new products/services, and achieve profitability.
• Launch sales initiative during the second quarter of the fiscal year ending March 31, 2026 (July-September 2025).
• Develop managed care agreements with southeastern states for Medicaid wound care patients.
• Negotiate with distributors in various Middle Eastern countries.
• Finalize the binding Letter of Intent with Colltech Limited into a definitive agreement by August 31, 2025.
• Develop a more detailed long-form contract with Colltech Limited by March 31, 2026, for scaled commercial operations.
• Address material weaknesses in internal control over financial reporting by seeking guidance from third-party experts and consultants.
• Repay the $2,400,000 note payable for technology platforms by August 16, 2025.
• Repay related party notes payable and notes payable to shareholder by September 30, 2025.
• Repay other notes payable to a relative of a former officer by June 30, 2026.

Key Dates

Recommendation

Regenerex Pharma, Inc. presents an extremely high-risk investment profile. The company reported a significantly widened net loss of $663,584 for Q2 2025, with zero revenue, indicating a complete lack of commercial traction despite having FDA-approved facilities and promising product efficacy. Cash reserves plummeted by over 73% in a single quarter to a critically low $172,430, while cash burn from operations surged. The explicit 'going concern' warning, coupled with total liabilities exceeding assets by over $4.5 million, signals severe financial distress and an unsustainable operational model without immediate and substantial external funding. Furthermore, the admission of ineffective internal controls over financial reporting due to material weaknesses raises serious concerns about financial transparency and management oversight. While the binding LOI with Colltech Limited and the clinical efficacy of QBx offer long-term potential, the immediate financial instability, heavy reliance on related-party financing, and the increased contingent consideration on future capital raises make the stock a 'strong sell' for any seasoned investor or institution, as the risk of significant capital loss is exceptionally high.

Keywords

Regenerex Pharma, RGPX, Wound Care, Biotechnology, SEC Filing, 10-Q, Quarterly Report, Financial Results, Net Loss, Going Concern, Cash Flow, Intellectual Property, QBx, Xcellderma, Accelerex, Colltech Limited, Ovine Collagen, Medical Device, Pharmaceutical, Chronic Wounds, Diabetic Ulcers, Pressure Ulcers, Burns, Surgical Wounds, FDA Approval, Capital Raise, Related Party Transactions, Internal Controls